For the abovementioned reason, this trial supported pembrolizumab as a new second-line standard of care for esophageal cancer with PD-L1 CPS ≥ 10 and encouraged furthers evaluations of checkpoints inhibitors in ESCC treatment. Here, CD274 is linked to esophageal squamous cell carcinoma.